Koch K R, Cursiefen C, Heindl L M
Zentrum für Augenheilkunde, Uniklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.
Ophthalmologe. 2017 May;114(5):416-423. doi: 10.1007/s00347-017-0466-2.
In recent years, the minimally invasive surgical procedure of transcanalicular laser-assisted dacryocystorhinostomy (TKL-DCR) has gained importance in the treatment of primary acquired nasolacrimal duct obstructions (PANDO).
Surgical indications, functional success rates, potential advantages, and complications of TKL-DCR are presented and compared with the standard procedures external (EXT-DCR) and endonasal DCR (EN-DCR).
The study comprises a PubMed literature review and our own clinical results.
Using TKL-DCR either as the primary surgical treatment for PANDO, or as a secondary procedure following failure (reobstruction of the surgical ostium) of previous EXT-DCR resulted in good functional success rates (60-90%). The duration of surgery (10-15 min) and the period of recovery are significantly shorter than in EXT-DCR. Visible cutaneous scars and significant postoperative nose bleeding are not among the complications of TKL-DCR, due to the lack of a skin incision and the coagulative ability of the diode laser. The smaller sized surgical ostium has been considered the main disadvantage of TKL-DCR, since it might be prone to earlier reobstruction. On the other hand, TKL-DCR spares the anatomical structures that form the physiological tear pump, which should favor tear drainage. In very few cases, thermal damage to the canaliculus has been observed as a complication.
Given the satisfying functional results, TKL-DCR is a valid alternative to the "gold standard" procedure EXT-DCR, especially in patients who particularly request speedy recovery and who do not want to take the risk of visible skin scaring. Future studies will have to investigate whether the smaller surgical ostia of TKL-DCR remain patent and whether functional success rates decrease during a longer follow-up period of >2 years.
近年来,经泪小管激光辅助泪囊鼻腔造口术(TKL-DCR)这种微创手术在原发性后天性鼻泪管阻塞(PANDO)的治疗中变得越来越重要。
介绍TKL-DCR的手术适应症、功能成功率、潜在优势及并发症,并与标准手术外部泪囊鼻腔造口术(EXT-DCR)和鼻内镜下泪囊鼻腔造口术(EN-DCR)进行比较。
本研究包括PubMed文献综述及我们自己的临床结果。
将TKL-DCR用作PANDO的主要手术治疗方法,或作为先前EXT-DCR失败(手术造口再阻塞)后的二次手术,均取得了良好的功能成功率(60%-90%)。手术时间(10-15分钟)和恢复时间明显短于EXT-DCR。由于没有皮肤切口以及二极管激光的凝血能力,可见的皮肤瘢痕和明显的术后鼻出血不属于TKL-DCR的并发症。较小的手术造口被认为是TKL-DCR的主要缺点,因为它可能更容易早期再阻塞。另一方面,TKL-DCR保留了形成生理性泪泵的解剖结构,这有利于泪液引流。在极少数情况下,观察到泪小管热损伤作为一种并发症。
鉴于令人满意的功能结果,TKL-DCR是“金标准”手术EXT-DCR的有效替代方法,特别是对于那些特别要求快速康复且不想冒可见皮肤瘢痕风险的患者。未来的研究将不得不调查TKL-DCR较小的手术造口是否保持通畅,以及在超过2年的更长随访期内功能成功率是否会降低。